63 results about "Dysbacterioses" patented technology

The invention discloses bifidobacterium animalis subsp. Lactis, a preparation and application of the bifidobacterium animalis subsp. Lactis in regulation of depression and intestinal flora. Belongs to the technical field of probiotic preparation. According to the application, seven strains of bacteria are separated from excrement of infants, the seven strains of bacteria comprise bifidobacterium breve, bifidobacterium animalis and bifidobacterium longum through identification, the anti-depression capacity of the seven strains of bacteria is evaluated through in-vitro experiments, a potential antidepressant bifidobacterium animalis subsp. Lactis BD1 is screened out, and further experiments prove that the antidepressant bifidobacterium animalis subsp. Lactis BD1 has the advantages that the antidepressant bifidobacterium animalis subsp. Lactis BD1 can be used for preparing the antidepressant bifidobacterium animalis subsp. Lactis BD1; the strain has the effects of improving depressive mood, intestinal bacteria unbalance and insufficient serotonin secretion in the brain caused by chronic bound stress (CRS), and compared with bifidobacterium animalis subsp. Lactis in the prior art, the strain achieves the anti-depression effect from multiple aspects, also has the effect of adjusting intestinal flora imbalance, and has the advantages of being safe and reliable. And a new treatment strategy is provided for depression and intestinal flora imbalance.

The invention belongs to the field of microorganisms. The invention provides an application of a probiotic composition in preparation of medicines for preventing and treating ulcerative colitis, the probiotic composition comprises a combination of bacillus coagulans and clostridium butyricum, and the combination of bacillus coagulans and clostridium butyricum comprises a combination of bacillus coagulans and clostridium butyricum. The bacillus coagulans is bacillus coagulans JSSW-LA-07-1 with the preservation number of CGMCC (China General Microbiological Culture Collection Center) No.10182, and the clostridium butyricum is clostridium butyricum JSIM-MCB20040312 with the preservation number of CGMCC No.1647. The bacillus coagulans and the clostridium butyricum are used for preparing the bacillus coagulans and the clostridium butyricum. The probiotic composition has the capacity of preventing and treating ulcerative colitis, the ulcerative colitis treating effect is better than that of positive control medicine salazosulfapyridine, the obvious ulcerative colitis treating effect is achieved, the inflammatory factor content and the oxidative stress level are remarkably reduced, inflammatory cell infiltration is reduced, intestinal flora imbalance is improved, and the effect of preventing and treating ulcerative colitis is achieved. Meanwhile, the effect of promoting planting of probiotics is achieved.

The invention discloses application of a bifidobacterium animalis subspecies F1-7 in preparation of a medicine for preventing or treating sarcopenia, belongs to the technical field of microorganism application, and provides application of the bifidobacterium animalis subspecies F1-7 in preparation of the medicine for preventing or treating sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-7 in preparation of drugs for improving bile acid metabolic function decline caused by sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-7 in preparation of a medicine for improving intestinal flora imbalance caused by sarcopenia. The invention finds that the bifidobacterium animalis subspecies F1-7 can effectively improve the skeletal muscle quality of mice with sarcopenia, improve the condition of tension reduction, regulate intestinal flora, promote bile acid metabolism and further relieve muscular atrophy, and enriches a probiotic library for improving sarcopenia.

The invention discloses application of a bifidobacterium animalis subspecies F1-3-2 in preparation of a medicine for preventing or treating sarcopenia, belongs to the technical field of microorganism application, and provides application of the bifidobacterium animalis subspecies F1-3-2 in preparation of the medicine for preventing or treating sarcopenia. The invention relates to an application of bifidobacterium animalis subspecies F1-3-2 in preparation of a medicine for correcting intestinal flora imbalance caused by sarcopenia. The invention finds that the bifidobacterium animalis subspecies F1-3-2 can effectively improve the skeletal muscle quality of mice with sarcopenia, improve the condition of tension reduction, improve the level of serum markers in sarcopenia, regulate the homeostasis of intestinal flora so as to relieve muscular atrophy, prepare freeze-dried bacterial powder and enrich products for improving sarcopenia.

The invention discloses combined prebiotic ferment powder and application thereof. The combined prebiotics ferment powder is a dried product obtained after the compound lactic acid bacteria composition is fermented; wherein the cell number ratio of each fermentation strain is as follows: LRH10 (12 + / -0.5%), LPC12 (2 + / -0.5%), LF26 (26.3 + / -0.5%), ST30 (21.6 + / -0.5%) and LH43 (38.1 + / -0.5%). According to the present invention, the combined probiotic fermentation powder has significant promotion effect on the growth of Bifidobacterium longum BL986, such that the combined probiotic fermentation powder can be used for preparing the drug for relieving the senile intestinal flora disorder.

The invention relates to a dental and / or oral care product comprising between 0.0039% and 0.0078% by weight of nisin establishing and / or maintaining a pH of at least 4.5 in situ. Although said rather low nisin concentration does not provide an anti-bacterial effect, it is surprisingly and advantageously capable of maintaining stable pH values of at least 4.5, thereby preventing destruction of a subject's teeth enamel based on enamel demineralization effects at pH below 4.5, and said low nisin concentration advantageously further avoids dysbacteriosis, i.e. the oral microflora remains balanced, thus not leading to an increase of e.g. periodontitis associated bacteria.

The disclosure is directed to methods for culturing, transferring, and maintaining a microbiota containing a predominance of a select group of beneficial microorganisms to alleviate and / or treat gut dysbiosis, including gastrointestinal symptoms thereof, in a subject suffering from dysbiosis.

Provided herein are methods for preventing or treating antibiotic induced dysbiosis in a patient by administering to the subject a composition comprising a micro sphere, a bio film-generating probiotic bacterium and a prebiotic, wherein the prebiotic comprises a nutritional supplementation for the probiotic bacterium.

The present invention is applicable to the field of biomedical technology, and provides a preparation method and application of multifunctional nanospheres targeting bacteria. The prepared targeted multifunctional nanospheres have both PDT / PTT functions and target harmful bacteria for antibacterial treatment of periodontitis. By using bismuth silver sulfide hollow nanospheres, photosensitizers and bacterial outer membrane vesicles as raw materials, the raw materials are cheap and the preparation process is simple. The prepared multifunctional nanospheres have unique advantages. They will not cause damage to probiotics, but can accurately target harmful bacteria and exert antibacterial effects, thereby effectively solving the problem of dysbacteriosis. In addition, the direct contact between the multifunctional nanospheres and bacteria will interfere with the electron transfer behavior of the bacteria, which is conducive to strengthening the bactericidal effect on bacteria. The adopted targeting strategy is extremely suitable for the treatment of dysbacteriosis diseases, showing a broad application prospect.

The prebiotic formulation is capable of modulating the growth and / or activity of microorganisms in a region of the urogenital system. Such prebiotic formulations can comprise isomaltulose and at least one other prebiotic, such as 1-kestose or lactulose. These modulated microorganisms can be directly related to the health of the urogenital system, and their modulation can be used to prevent, control or treat dysbacteriosis in the region of the urogenital system.

Provided herein are compositions comprising Escherichia coli (E. coli), Saccharomyces boulardii (S. boulardii), Lactobacillus plantarum (L. plantarum), and / or Ensifer meliloti (E. meliloti) and a first stabilizing excipient. Also provided herein are methods of delivering E. coli, S. boulardii, L. plantarum, and / or E. meliloti to a subject in need thereof, methods of inducing bacterial growth in a subject or in a cell, tissue, or biological sample, and methods of inhibiting an enteric pathogen in a subject or in a cell, tissue, or biological sample. Further provided herein are methods of treating dysbiosis in a subject in need thereof.

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, comprising combinations or formulations of microbes, such as non-pathogenic, live bacteria and / or bacterial spores, for example as probiotics, for the control, amelioration, prevention, and treatment of a disease or condition, for example, a dysbiosis, or for augmenting the health or ability to thrive in an individual. In alternative embodiments, provided are compositions or formulations, including products of manufacture and kits, and methods, comprising at least one non-pathogenic, live bacteria and / or bacterial spore and at least one probiotic, or synbiotic. In alternative embodiment, these non-pathogenic, live bacteria and / or bacterial spores (and optionally also a probiotic) are administered to an individual in need thereof, thereby resulting in a modification or modulation of the individual's gut microfloral population(s).

The invention discloses a preparation method for constructing a mouse embryo implantation failure model based on fusobacterium variabilis, and belongs to the technical field of animal models. The method comprises the following steps: carrying out anaerobic culture on fusobacterium varium, giving the fusobacterium varium to a female C57 mouse through an intragastric administration way, continuously treating for 28 days, and inducing the female C57 mouse to have a phenotype that the number of implanted embryos is reduced and the expression of a vascular endothelial growth factor (VEGF) in a uterine tissue is reduced. According to the method, embryo implantation failure caused by intestinal flora imbalance is simulated through the'intestine-uterus axis' for the first time, a reliable animal model is provided for studying the causal relationship between flora and pregnancy failure, and the method has important scientific research and clinical application value.

Provided herein are pharmaceutical compositions comprising a bacterial population. The bacterial population comprises one bacterial strains or at least two bacterial strains. Such pharmaceutical compositions can be administered to a subject for prevention and / or treatment of dysbiosis and dysbiosis associated conditions and diseases, such as infant gastrointestinal diseases.

Oral composition comprising glutamate, or glutamine, solvate or hydrate thereof, for use in the treatment and / or prevention of caries, wherein the composition is orally administered and increases the pH of the saliva, reducing the risk of caries development. Said oral composition increases the amount of health-associated bacteria and / or decreases the amount of disease-associated bacteria and is useful for the treatment and / or prevention of oral diseases, such as periodontal diseases, halitosis and diseases caused by Candida. Method to determine the response of a mammal to the treatment with glutamate, or with glutamine, solvate or hydrate thereof, comprising determining in saliva the amount of health-associated or disease-associated bacteria or a dysbiosis index, and identifying the mammal as responsive or non-responsive to the treatment.

The invention belongs to the technical field of biology, and discloses a pediococcus acidilactici strain capable of relieving constipation and diarrhea, the name of the pediococcus acidilactici strain is P48, the classification name of the pediococcus acidilactici strain is pediococcus acidilactici, the preservation number of the pediococcus acidilactici strain is CGMCC No.27885, the preservation date of the pediococcus acidilactici strain is July 13, 2023, and the preservation unit of the pediococcus acidilactici strain is China General Microbiological Culture Collection Center, No. 3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing. The pediococcus acidilactici P48 can tolerate the gastrointestinal tract environment, improves the survival rate of the gastrointestinal tract, is beneficial to strain colonization, and can be used for preparing functional microbial agents, food and medicines for relieving constipation or diarrhea; the pediococcus acidilactici P48 disclosed by the invention can be used for carrying out bidirectional regulation on diarrhea and constipation at the same time; meanwhile, intestinal flora imbalance can be improved, immune system activation is promoted, inflammatory factor release is inhibited, and the gastrointestinal tract function is improved.

The present invention relates to a method for isolating and identifying a keystone microorganism in an ecosystem of interest. This keystone microorganism carries at least one metabolic function involved in an altered metabolic pathway in a representative sample of the ecosystem. This altered metabolic pathway is then responsible for dysbiosis.

The present invention is directed, inter alia, to compositions comprising a population of at least one strain of bacteria at least partially attached to particles, the particles comprise (i) a polysaccharide-based material; and (ii) a metal carbonate. Uses of the compositions, e.g., for prevention or treatment of dysbiosis, and methods for the preparation thereof are further provided herein.

The present application belongs to the technical field of microbial prevention and treatment, and particularly relates to a mycobacterium phage and application thereof. Specifically, the present application successfully screens a mycobacterium phage MP1 capable of precisely targeting and killing mycobacterium marinum, which can precisely target and kill specific mycobacterium marinum without causing adverse effects on normal flora. This feature enables the phage therapy to avoid the adverse reactions and flora imbalance problems caused by antibiotic treatment when treating drug-resistant mycobacterium marinum. Meanwhile, the above-mentioned mycobacterium phage MP1 is obtained from nature and is easy to be industrialized, and a drug or environmental disinfectant prepared from the above-mentioned phage not only can reduce the cost, but also has the advantages of green environmental protection and the like, and therefore has good practical application value.

The present invention relates to novel and stable preparations of bacterial extracts that exhibit considerably greater stability over time, to new methods of preparing them, to pharmaceutical formulations based on these new stabilized bacterial extracts, as well as to new routes of administration and delivery devices for the treatment and / or prevention of acute and chronic immunological disorders resulting from infections, inflammation, neoplasms, or dysbiosis.

The present invention relates to a composition for use in the prevention and / or treatment of dysbiosis. It also relates to the use of said composition for the preparation of a medicament for the prevention and / or treatment of dysbiosis. Furthermore, it relates to a method of preventing and / or treating dysbiosis wherein said composition is administered to a subject in need thereof.SOLUTION: A composition for use in the treatment and / or prevention of signs and / or symptoms associated with atopic dermatitis dysbiosis, xeroderma dysbiosis or oral aphthous dysbiosis, the composition comprising an olive product, trimethylglycine and xylitol, the composition comprising between 0.05% and 4.1% by weight of the olive product; A composition, wherein the olive product is olive oil and / or olive fruit extract; for use for the treatment of dysgeusia (taste disturbance or taste loss) associated with mucosal dysbiosis and / or pulmonary dysbiosis, or for the prevention of dehydration, dry cough and / or cold associated with dysbiosis, wherein the composition comprises an olive product, trimethylglycine and xylitol, wherein the composition comprises between 0.05% and 4.1% by weight of the olive product, and wherein the olive product is olive oil and / or olive fruit extract.SELECTED DRAWING: None

Provided herein are postbiotic compositions prepared using successive fermentation methods of specific bacteria and plant fiber material. Also provided herein are methods, including for the treatment or prevention of the disruption of gut microbiota, or dysbiosis, associated with an antibiotic treatment, chemotherapy treatment, or administration of a dysbiosis-causing medications or medical treatments, using said postbiotic compositions, or for improving responses and / or reducing complications to treatments such as antibiotics or chemotherapy. Such postbiotic compositions can also be used for the treatment or prevention of the disruption of the gut-brain axis, including to treat or prevent neurological diseases or disorders, such as synucleinopathies, including but not limited to Parkinson's disease.

A microbiome modulating composition and a method for producing the microbiome modulating composition are described herein. The method comprises preparing a culture from at least two of any Lactobacillus spp. bacteria, Limosilactobacillus spp. bacteria, or combinations thereof, passaging the culture on a glycogen carbon source to form a postbiotic ferment of the at least two of any Lactobacillus spp. bacteria, Limosilactobacillus spp. bacteria, or combinations thereof, and adding the postbiotic ferment to a carrier. Further disclosed is a method for treating microbial dysbiosis of an urogenital area or a skin area of a user, the method comprising applying the microbiome modulating composition to an urogenital or a skin area of a user. The disclosed methods and microbiome modulating compositions help promote the growth of healthy Lactobacillus spp. bacteria to prevent dysbiosis and other related conditions and infections.

Provided herein are bacterial compositions that are useful for treating and preventing complications and side effects associated with a disease or disorder, such as those associated with dysbiosis of a gastrointestinal tract. The bacterial compositions disclosed herein are designed to exhibit one or more functional features that are useful for the treatment of such diseases and disorders.

The invention discloses a microecological preparation capable of regulating and controlling abundance of intestinal bifidobacteria in a targeted mode and application of the microecological preparation, the microecological preparation is composed of intestinal symbiotic bacteria and prebiotics, the intestinal symbiotic bacteria are bacteroides, and the prebiotics are polysaccharide containing N-acetylglucosamine. The prebiotics and the bacteroides multiforme CCFM1441 are combined for use, the prebiotics N-acetylglucosamine can be effectively released, nutrition is provided for bifidobacterium longum, and proliferation of the bifidobacterium longum is promoted. Further, in vitro and in vivo experiments prove that there is a strong cross-feeding activity between Bacteroides multiforme CCFM1441 and Bifidobacterium longum based on prebiotics. The beneficial microecological preparation can promote proliferation of bifidobacterium longum in intestinal tracts in a targeted manner, improves intestinal flora imbalance caused by antibiotics, and further has a huge application prospect in preparation of products (such as food, drugs or health care products) for improving intestinal health.

A programmable drug-delivery system comprising a chassis cell, (e.g., a Molecularly Encoded Memory via an Orthogonal Recombinase arraY (MEMORY)) engineered to produce an orthogonal inducible recombinase to alter extrachromosomal nucleic acid. Also disclosed herein is a synthetic probiotic composition comprising the programmable drug-delivery system, described herein, and a pharmaceutically acceptable carrier, and the methods of use thereof in preventing or treating gut microbiota dysbiosis in a subject in need thereof.

The disclosure relates generally to bacterial strains of the genus Christensenella, e.g., Christensenella sp. P152-H6d bacterial strains, and compositions comprising such bacterial strains. The disclosure further relates to methods of using such bacterial strains and compositions for preventing or treating a disorder, e.g., an inflammatory disorder, a gastrointestinal disorder, a metabolic disorder, and / or dysbiosis.

The invention discloses a preparation method of a ficus microcarpa extract and application of the ficus microcarpa extract in intestinal flora disorder caused by circadian rhythm disorder. Pharmacological experiments prove that the ficus striata flavone has a remarkable regulating effect in a circadian rhythm disorder injury model: the ficus striata flavone can be used for effectively solving the problems that the diversity of intestinal flora is reduced, the excessive propagation of firmictures, the expression of Bacteroidetes is reduced and the like, which are caused by circadian rhythm disorder, and can be used for preventing and treating the diseases caused by circadian rhythm disorder, so that the ficus striata flavone can be used for preventing and treating the diseases caused by circadian rhythm disorder. Meanwhile, circadian rhythm oscillation of key bacteria such as prevotella, Bacteroides and Clostridium can be adjusted, and increase of the F / B ratio is reduced, so that the rhythm and stability of intestinal flora are improved. The invention simultaneously discloses two preparation processes, namely an ethanol reflux-resin purification method and a water extraction-concentration-alcohol precipitation method, so that the stable quality of the extract is ensured, and the industrial feasibility is realized.